@article { author = {Hirata, Munetsugu and Shinden, Yoshiaki and Nagata, Ayako and Nomoto, Yuki and Saho, Hazuki and Nakajo, Akihiro and Arigami, Takaaki and Kurahara, Hiroshi and Maemura, Kosei and Natsugoe, Shoji and Kijima, Yuko}, title = {Clinical Features of Breast Cancer Patients with Human T-Cell Lymphotropic Virus Type-1 Infection}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {20}, number = {6}, pages = {1909-1912}, year = {2019}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2019.20.6.1909}, abstract = {Background: Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that causes adult T-cell leukemia/lymphoma (ATL), an aggressive form of T-cell malignancy. The relationship between HTLV-1 infection and cancerprogression is controversial. HTLV-1 encodes oncogenic protein TAX1 and it is hypothesized that HTLV-1 infectionis associated with breast cancer progression. In this study, we evaluated the relationship between HTLV-1 infectionand clinicopathological factors in breast cancer patients. Methods: We retrospectively analyzed 610 patients withprimary breast cancer who underwent surgical treatment without preoperative chemotherapy at Kagoshima UniversityHospital between January 2001 and January 2015. Results: When patients with and without HTLV-1 infection werecompared, no differences in clinicopathological factors were observed, except for age. Disease-free survival andoverall survival rates did not differ between groups. Conclusions: HTLV-1–positive patients were significantly olderthan HTLV-1–negative patients. It was supposed to be due to the fact that the HTLV-1 infection rate is decreasing. Anyeffect of HTLV-1 infection on breast cancer progression appears to be negligibly small.}, keywords = {HTLV-1,breast cancer,clinicopathological factors}, url = {https://journal.waocp.org/article_88608.html}, eprint = {https://journal.waocp.org/article_88608_73c353a54ecb25ea5d1eb7352c222059.pdf} }